Disease staging: CliniCal anD CoDeD Criteria - HCUP

Clinical Criteria with Description, Diagnostic Findings and ICD-9-CM codes
DXCat Number: HEM21
MultiStage: No
DXCat Label: Neoplasm, Malignant: Leukemia, Chronic Myelogenous Specificity: A
Etiology: Neoplasm
Stage Description Diagnostic findings ICD-9-CM Codes
0.00 History or remission of chronic myelocytic
leukemia
DX 20511, 20581, 20591, V1062;
1.01 Chronic myelogenous leukemia Chronic myelogenous leukemia [peripheral smear report or bone marrow aspiration report or bone
marrow biopsy report]
OR neutrocytosis:
AND Philadelphia chromosome positive [chromosome analysis report]
OR splenomegaly
OR bcr-abl gene [cytogenetics report or Southern Blot report]
DX 20510, 20512, 20580, 20582,
20590, 20592;
2.01 with significant anemia Stage 1.01
AND hemoglobin ≤ 7 gm/dl [CBC report]
2.02 with significant thrombocytopenia Stage 1.01-2.01
AND platelets < 60,000 cells/mm 3 [CBC report]
2.03 with significant leukocytosis Stage 1.01-2.02
AND total WBC count >50,000 cells/mm 3 [CBC report]
2.04 with blast crisis Stage 1.01-2.03
AND blast cells ≥ 30% of bone marrow cell count [bone marrow report]
2.05 with chloromas or hepatosplenomegaly Stage 1.01-2.04
AND chloromas, myeloblast tumors in skin or lymph nodes or bone or liver or spleen
[operative/pathology report]
OR
2.06 with severe thrombocytopenia Stage 1.01-2.05
AND platelets < 20,000 cells/mm 3 [CBC report]
2.07 with acute bleeding Stage 1.01-2.06
AND bleeding:
3.01 with sepsis Stage 1.01-2.07
AND sepsis:
3.02 with shock Stage 1.01-3.01
AND shock:
4.00 with death Stage 1.01-3.02
AND death
hepatosplenomegaly [physical examination report or sonography report or CT scan
report]
STAGE 1.01 + GROUP
ANEM_NEOPL;
STAGE 1.01-2.01 + GROUP
THRMBCYTPEN;
STAGE 1.01-2.02 + GROUP
LEUKOCYTOSIS;
NO;
STAGE 1.01-2.03 + (DX 3383,
20530, 5718, 7891, 7892, 78951);
NO;
STAGE 1.01-2.05 + DX 4590;
STAGE 1.01-2.07 + GROUP SEPSIS;
STAGE 1.01-3.01 + (GROUP
SHOCKC OR GROUP SHOCKN) ;
NO;
Thursday, January 07, 2010 9:22:08 AM
©2010 Thomson Reuters. All rights reserved.